IGMS logo

IGM Biosciences, Inc. Common Stock

IGMS

IGMS: IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 protein, IGM-8444, a combination with a chemotherapeutic agent such as irinotecan, gemcitabine, or venetoclax, and IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.

more

Show IGMS Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of IGMS by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Quiver Logo

No Whale Activity for this ticker

Institutional Holdings Dashboard
Insider Trading

Quarterly net insider trading by IGMS's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $230,000 Jul 17, 2023 Issue: Medical/Disease Research/Clinical Labs
  • $230,000 Apr 20, 2023 Issue: Medical/Disease Research/Clinical Labs
  • $210,000 Jan 20, 2023 Issue: Medical/Disease Research/Clinical Labs
  • $190,000 Oct 20, 2022 Issue: Medical/Disease Research/Clinical Labs
  • $130,000 Jul 20, 2022 Issue: Medical/Disease Research/Clinical Labs
  • $130,000 Apr 20, 2022 Issue: Medical/Disease Research/Clinical Labs
  • $140,000 Jan 20, 2022 Issue: MEDICAL/DISEASE RESEARCH/CLINICAL LABS
  • $10,000 Oct 18, 2021 Issue: Medical/Disease Research/Clinical Labs
  • $10,000 Jul 15, 2021 Issue: Medical/Disease Research/Clinical Labs
  • $10,000 Apr 15, 2021 Issue: Medical/Disease Research/Clinical Labs
U.S. Patents

New patents grants

  • Patent Title: Binding molecules with modified j-chain May. 02, 2023
  • Patent Title: Polynucleotides encoding death domain-containing receptor-5 (dr5) binding molecules Feb. 14, 2023
  • Patent Title: Modified j-chain Jan. 17, 2023
  • Patent Title: Binding molecules with modified j-chain Jan. 03, 2023
  • Patent Title: Multi-valent hepatitis b virus antigen binding molecules and uses thereof Dec. 27, 2022
  • Patent Title: Modified human igm constant regions for modulation of complement-dependent cytolysis effector function Aug. 02, 2022
  • Patent Title: Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof Dec. 07, 2021
  • Patent Title: Modified j-chain Apr. 13, 2021
  • Patent Title: Anti-pd-l1 antibodies Mar. 23, 2021
  • Patent Title: Igm fc and j-chain mutations that affect igm serum half-life Jan. 26, 2021
  • Patent Title: Iga multi-specific binding molecules Nov. 03, 2020
  • Patent Title: Multimeric bispecific binding molecules specific for cd20 and cd3 Sep. 29, 2020
  • Patent Title: Multimeric death domain-containing receptor-5 (dr5) antibodies and uses thereof Jun. 23, 2020
  • Patent Title: Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof Feb. 25, 2020
  • Patent Title: Modified j-chain Sep. 03, 2019
  • Patent Title: Constant chain modified bispecific, penta- and hexavalent ig-m antibodies Jul. 16, 2019
  • Patent Title: Modified j-chain Apr. 24, 2018
  • Patent Title: Tumor necrosis factor (tnf) superfamily receptor igm antibodies and uses thereof Apr. 10, 2018
  • Patent Title: Antibody induced cell membrane wounding Oct. 04, 2016
  • Patent Title: Cdim binding proteins and uses thereof Aug. 09, 2016
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of IGMS in WallStreetBets Daily Discussion

IGMS News

Recent insights relating to IGMS

CNBC Recommendations

Recent picks made for IGMS stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in IGMS

Corporate Flights

Flights by private jets registered to IGMS